Blocking this myeloid checkpoint CD47-SIRP⍺ axis using anti-CD47 antibody therapy was shown to limit tumor growth in both adult and pediatric gliomas [40,41] and also promoted M1 activation of TAMs [42]. The gene discussed is CD47; the disease is central nervous system cancer.